Akero Therapeutics, Inc.

NasdaqGS:AKRO Stock Report

Market Cap: US$4.3b

Akero Therapeutics Valuation

Is AKRO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AKRO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

US$28.62
Fair Value
62.4% overvalued intrinsic discount
6
Number of Analysts

Below Fair Value: Insufficient data to calculate AKRO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AKRO's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AKRO?

Key metric: As AKRO is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for AKRO. This is calculated by dividing AKRO's market cap by their current book value.
What is AKRO's PB Ratio?
PB Ratio4.2x
BookUS$1.03b
Market CapUS$4.31b

Price to Book Ratio vs Peers

How does AKRO's PB Ratio compare to its peers?

The above table shows the PB ratio for AKRO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average9.5x
NAMS NewAmsterdam Pharma
5.4x29.39%US$4.2b
KYMR Kymera Therapeutics
4.2x-10.30%US$4.1b
SRRK Scholar Rock Holding
16.3x41.96%US$3.8b
ACLX Arcellx
12.3x49.53%US$4.8b
AKRO Akero Therapeutics
4.2x14.29%US$4.3b

Price-To-Book vs Peers: AKRO is good value based on its Price-To-Book Ratio (4.2x) compared to the peer average (9.5x).

Price to Book Ratio vs Industry

How does AKRO's PB Ratio compare vs other companies in the US Biotechs Industry?

52 CompaniesPrice / BookEstimated GrowthMarket Cap
NKTX Nkarta
0.4x1.69%US$153.41m
ZNTL Zentalis Pharmaceuticals
0.4x13.87%US$121.19m
XBIT XBiotech
0.4xn/aUS$77.44m
ARTV Artiva Biotherapeutics
0.5x-9.92%US$68.64m
AKRO 4.2xIndustry Avg. 2.5xNo. of Companies76PB0246810+
52 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: AKRO is expensive based on its Price-To-Book Ratio (4.2x) compared to the US Biotechs industry average (2.5x).

Price to Book Ratio vs Fair Ratio

What is AKRO's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AKRO PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio4.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate AKRO's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AKRO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$53.88
US$64.83
+20.33%
30.57%US$109.00US$54.00n/a6
Oct ’26US$46.55
US$77.30
+66.06%
15.32%US$109.00US$64.00n/a10
Sep ’26US$46.73
US$76.27
+63.22%
16.12%US$109.00US$60.00n/a11
Aug ’26US$48.37
US$76.30
+57.74%
16.90%US$109.00US$60.00n/a10
Jul ’26US$51.41
US$76.30
+48.41%
16.90%US$109.00US$60.00n/a10
Jun ’26US$49.65
US$76.30
+53.68%
16.90%US$109.00US$60.00n/a10
May ’26US$45.31
US$77.64
+71.34%
16.42%US$109.00US$60.00n/a11
Apr ’26US$38.64
US$77.64
+100.92%
16.42%US$109.00US$60.00n/a11
Mar ’26US$49.12
US$77.36
+57.50%
16.59%US$109.00US$60.00n/a11
Feb ’26US$54.08
US$78.27
+44.74%
16.97%US$109.00US$60.00n/a11
Jan ’26US$27.82
US$48.27
+73.52%
18.51%US$65.00US$35.00n/a11
Dec ’25US$32.10
US$48.27
+50.38%
18.51%US$65.00US$35.00n/a11
Nov ’25US$32.33
US$46.10
+42.59%
18.26%US$60.00US$30.00n/a10
Oct ’25US$28.83
US$46.10
+59.90%
18.26%US$60.00US$30.00US$46.5510
Sep ’25US$27.20
US$46.10
+69.49%
18.26%US$60.00US$30.00US$46.7310
Aug ’25US$26.35
US$44.56
+69.09%
16.63%US$56.00US$30.00US$48.379
Jul ’25US$23.16
US$44.56
+92.38%
16.63%US$56.00US$30.00US$51.419
Jun ’25US$18.82
US$45.13
+139.77%
17.00%US$56.00US$30.00US$49.658
May ’25US$20.08
US$47.50
+136.55%
16.97%US$59.00US$30.00US$45.318
Apr ’25US$24.07
US$51.25
+112.92%
11.07%US$60.00US$42.00US$38.648
Mar ’25US$27.81
US$43.25
+55.52%
22.79%US$60.00US$33.00US$49.128
Feb ’25US$20.98
US$42.88
+104.36%
23.13%US$60.00US$33.00US$54.088
Jan ’25US$23.35
US$42.88
+83.62%
23.13%US$60.00US$33.00US$27.828
Dec ’24US$17.66
US$42.88
+142.78%
23.13%US$60.00US$33.00US$32.108
Nov ’24US$13.21
US$43.56
+229.72%
20.82%US$60.00US$33.00US$32.339
Oct ’24US$50.58
US$67.89
+34.22%
10.61%US$83.00US$59.00US$28.839
US$77.3
Fair Value
39.9% undervalued intrinsic discount
6
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/12 01:47
End of Day Share Price 2025/10/10 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Akero Therapeutics, Inc. is covered by 25 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason ZemanskyBofA Global Research
Alexandria HammondBofA Global Research
Edward NashCanaccord Genuity